Details

Autor(en) / Beteiligte

• Jaffe, Susan

Titel

US Congress lets Medicare negotiate lower drug prices

Ist Teil von

• The Lancet (British edition), 2022-08, Vol.400 (10352), p.551-552

Ort / Verlag

London: Elsevier Ltd

Erscheinungsjahr

2022

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• Shattering decades of opposition from the pharmaceutical industry and its allies, slim Democratic majorities in the US House of Representatives and Senate have passed landmark legislation to begin to control runaway drug prices for almost 50 million older Americans with Medicare's pharmaceutical benefit. In addition to requiring that Medicare negotiate some prescription drug prices directly with manufacturers, other health-care provisions restrict price increases to the rate of inflation, limit patients’ co-pays for insulin to $35 a month, and expand premium subsidies for people on low-incomes covered by Medicare and the Affordable Care Act martketplace health insurance. According to the Senate Democratic leadership, prescription drug pricing reform would generate most of the savings, about $265 billion by 2030. “The bill doesn't address every issue with prescription drug pricing, including patent abuses and expanding protections for the private market”, said Senior Vice President of Government Affairs Bill Sweeney.